----item----
version: 1
id: {5C1660EE-A9FA-48C0-9BE9-0F11E6C6FD1F}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/09/23/FDA Reviews Sanofis Lixisenatide With CV Outcomes Data
parent: {E8CB3B12-58E6-4D8C-926D-C49922785188}
name: FDA Reviews Sanofis Lixisenatide With CV Outcomes Data
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 78f61706-e316-4539-a810-7abe04f20d06

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 55

FDA Reviews Sanofi's Lixisenatide With CV Outcomes Data
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 54

FDA Reviews Sanofis Lixisenatide With CV Outcomes Data
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 2339

<p>Sanofi revealed that its new drug application (NDA) for its once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide is under review at the FDA, which is evaluating the experimental medicine as a treatment for type 2 diabetes.</p><p>Sanofi did not disclose an expected FDA action date on the lixisenatide NDA, which was based on the results from the company's Phase III GetGoal clinical program, which enrolled more than 5,000 patients worldwide.</p><p>The NDA also includes findings from the recently-completed ELIXA cardiovascular outcomes trial (CVOT), which evaluated the CV safety of lixisenatide versus standard of care in more than 6,000 adults with type 2 diabetes with high CV risk, like patients who have recently experienced a spontaneous acute coronary syndrome event.</p><p>Sanofi pointed out that the lixisenatide NDA is the first U.S. application under review for a GLP-1 receptor agonist to include data from a completed CVOT.</p><p>The French drug maker licensed lixisenatide from Zealand Pharma A/S.</p><p>The medicine is sold in Europe and other parts of the world under the brand name Lyxumia, but the proprietary name in the U.S. is still under consideration, Sanofi said.</p><p>Sanofi <a href="http://www.scripintelligence.com/researchdevelopment/Sanofis-LixiLan-Succeeds-In-Second-Pivotal-Trial-But-Benefit-Still-Uncertain-360468" target="_new">also reported this month</a> that its combination of Lantus (insulin glargine [rDNA origin] injection 100 U/mL) plus lixisenatide, known as LixiLan, met its primary endpoint in a second Phase III study &ndash; demonstrating a statistically improved reduction in A1c.</p><p>Sanofi said it plans to submit an NDA for LixiLan in the fourth quarter. </p><p>Lantus and Sanofi's recently approved follow-up medicine Toujeo (insulin glargine [rDNA origin] injection, 300U/mL) are facing new competition in the U.S. from Novo Nordisk's two newly approved long-acting insulins Tresiba (insulin degludec injection) and Ryzodeg (insulin degludec/insulin aspart injection), which <a href="http://www.scripintelligence.com/home/Novo-Diabetes-Drugs-Tresiba-Ryzodeg-OKd-Pressures-Sanofi-360695" target="_new">gained the FDA's approval on Sept. 25</a> as therapies to improve glycemic control in patients with types I and II diabetes.</p><p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 258

<p>Sanofi revealed that its new drug application (NDA) for its once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide is under review at the FDA, which is evaluating the experimental medicine as a treatment for type 2 diabetes.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 54

FDA Reviews Sanofis Lixisenatide With CV Outcomes Data
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150923T181058
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150923T181058
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150923T181058
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC029908
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 55

FDA Reviews Sanofi's Lixisenatide With CV Outcomes Data
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 13

Headline News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

360643
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042457Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

78f61706-e316-4539-a810-7abe04f20d06
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042457Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
